Evidence map›Paper›PMID 37775669›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Melt Processing Virus-Like Particle-Based Vaccine Candidates into Biodegradable Polymer Implants.

Armando A Puente, Oscar A Ortega-Rivera, David M Wirth, Jonathan K Pokorski, Nicole F Steinmetz

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Armando A PuenteDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA.
Oscar A Ortega-RiveraDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
David M WirthDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
Jonathan K PokorskiDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, USA.
Nicole F SteinmetzDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA. nsteinmetz@eng.ucsd.edu.
University of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melt processing is an emerging production method to efficiently encapsulate proteins into polymeric devices for sustained release. In the context of vaccines, melt processing is well-suited to develop vaccine delivery devices that are stable outside the cold chain and can generate protective immunity from a single dose. We have demonstrated the compatibility of bacteriophage Qβ virus-like particles (VLPs) with hot-melt extrusion (HME) and have leveraged this technology to develop a single-dose vaccine candidate for vaccination against human papillomavirus (HPV). Here, we detail the methods for chemically conjugating an HPV peptide epitope from the L2 minor capsid protein to Qβ VLPs to generate HPV-Qβ particles. We outline techniques used to characterize HPV-Qβ particles, and we elaborate on the process to encapsulate HPV-Qβ into biodegradable poly(lactic-co-glycolic acid) (PLGA) implants and discuss methods for the materials characterization of the HPV-Qβ/polymer melts. The methods described could be adapted to other disease targets, i.e., by conjugation of a different peptide epitope, or transferred to other VLP systems suited for conjugation, immune response, or stability during processing. Such VLPs are ideally suited for use in HME, a mature, scalable, continuous, and solvent-free process which can be adapted to mold devices, therefore allowing the processing of the melts into various geometries, such as subcutaneous implants, or self-administrable microneedle patches.

Indexed as

Oncogene Proteins, ViralPapillomavirus InfectionsPapillomavirus VaccinesVaccines, Virus-Like ParticleAbsorbable ImplantsAntibodies, ViralCapsid ProteinsEpitopesHumansNeutralization TestsPeptidesPolymersAntibodies, ViralCapsid ProteinsEpitopesOncogene Proteins, ViralPapillomavirus VaccinesPeptidesPolymersVaccines, Virus-Like ParticleBacteriophage QβHuman papillomavirus (HPV)L2 capsid proteinMelt processingPolymer implantsSingle-dose vaccinesSustained releaseVaccinesVirus-like particles (VLP)

Identifiers

PMID37775669
OpenAlexW4387162473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.